Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.
D000818:Animals; D006168:Guinea Pigs; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000009:adverse effects / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008113:Liver Neoplasms / Q000628:therapy*; D008175:Lung Neoplasms / Q000628:therapy*; D008213:Lymphocyte Activation; D051379:Mice
D007376:Interleukin-2